BioNTech (NASDAQ:BNTX) CEO Sells $3,260,880.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 31,500 shares of BioNTech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00. Following the completion of the transaction, the chief executive officer owned 781,709 shares of the company’s stock, valued at $80,922,515.68. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Stock Down 1.8%

BNTX stock opened at $96.40 on Friday. The stock has a 50-day simple moving average of $97.00 and a two-hundred day simple moving average of $95.37. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The firm has a market capitalization of $24.38 billion, a PE ratio of -12.31 and a beta of 1.29. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the business posted ($1.60) earnings per share. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP raised its stake in shares of BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in BioNTech during the 2nd quarter valued at approximately $39,000. Nykredit A S purchased a new stake in BioNTech in the 2nd quarter worth approximately $293,000. B. Metzler seel. Sohn & Co. AG grew its position in shares of BioNTech by 66.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after buying an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of BioNTech during the second quarter valued at approximately $2,520,000. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on BNTX. Citigroup cut their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Finally, Morgan Stanley dropped their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.